Table 3. Toxoplasmosis occurrence and outcomes for HSCT and SOT patients, according to prophylaxis, Europe, 2010–2014*.
| Characteristic | HSCT, no. (%), n = 58† | SOT, no. (%), n = 29‡ | p value |
|---|---|---|---|
| Seropositive before transplantation | 41/46 (89)§ | 4/24 (17)¶ | <0.0001 |
| Diagnosis during chemoprophylaxis | 9/50 (18) | 5/28 (18) | NS |
| Diagnosis after chemoprophylaxis |
9/50 (18) |
8/28 (29) |
NS |
| 2-mo survival rate | |||
| With prophylaxis | 13/18 (72) | 17/17 (100) | <0.05 |
| Without prophylaxis |
18/32 (56) |
9/11 (82) |
0.1657 |
| 6-mo survival rate | |||
| With prophylaxis | 9/18 (50) | 17/17 (100) | 0.01 |
| Without prophylaxis | 9/32 (28) | 7/11 (64)# | 0.0679 |
*HSCT, hematopoietic stem cell transplant; NS, not significant; SOT, solid organ transplant. †Prophylaxiis data missing for 8 patients. ‡Prophylaxis data missing for 1 patient; incomplete information regarding dates of onset and/or stop of cotrimoxazole for 4 patients. §Serology data missing data for 4 patients. ¶Serology data missing data for 4 patients. #p<0.05 between SOT with or without chemoprophylaxis.